BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1799@azbio.org DTSTART;TZID=America/Phoenix:20230928T100000 DTEND;TZID=America/Phoenix:20230928T170000 DTSTAMP:20230925T150935Z URL:https://www.azbio.org/events/health-innovation-showcase-2023 SUMMARY:AZAdvances Health Innovation Showcase - ASU Health Futures Center - 28 Sep 23 10:00 DESCRIPTION:\nJoin us at the ASU Health Futures Center \nfor a look at Ariz ona's Health Innovation Pipeline\n[caption id="attachment_38289" align="al ignright" width="300"] The ASU Health Futures Center is home of the Mayo C linic and ASU Alliance for Health Care. Through the alliance the two organ izations have a shared goal of bringing the brightest minds together to ac celerate cutting-edge research discoveries\, improve patient care through innovation\, and transform medical education to enhance health outcomes at individual\, community and national levels. The state-of-the-art facility supports interdepartmental research and collaborative programs with Mayo Clinic — including ASU’s College of Health Solutions\, Edson College o f Nursing and Health Innovation\, Ira A. Fulton Schools of Engineering\, a nd the J. Orin Edson Entrepreneurship and Innovation Institute.[/caption]\ nThursday\, September 28\, 2023\nASU Health Futures Center\n6161 E. Mayo B lvd.\, Phoenix\, AZ 85054\n10:00 am - 5:00 pm\n\nREGISTER\n\n AZBio Membe rs: \;  \;  \;  \;$85.00\n Non Members: \;  \; &n bsp\;  \;  \;$185.00\n Full Time Students: \; $50.00\n Elect ed Leaders and Credentialed Media receive complimentary registration.\n\nS ponsorship Opportunities\n\n Presenting Sponsor (3 available) \; &nbs p\;  \; $10\,000.00\n\n includes recognition and 10 tickets\n\n\n Re ception sponsor (2 available) \;  \;  \;  \; $ \; &nbs p\;5\,000.00\n\n includes recognition and 5 tickets\n\n\n Video Sponsor (1 available) \;  \;  \;  \;  \;  \;  \;   \; $ \;  \;5\,000.00\n\n includes recognition and 5 tickets\n\n\n \n\n\n\nAgenda\n9:00 AM \;  \;  \;  \;Registration Opens - Networking Time\n\n10:00 AM \;  \;  \;Welcome\n\n10:15 AM&nbs p\;  \;  \;  \;Life in the Fast Lane\n\n \n\n \n\n MaryAnn Guerra\, President &\; Founder\, Aesthetics Biomedical\n Richard J. Mo rello\, CEO\, CND Life Sciences\, \;\n Richard Austin\, CEO\, Reglage ne\, \;\n Moderator: \; Kristen Swingle\, President &\; COO\, Critical Path Institute\n\n\n\n\n\n11:00 AM \;  \;  \;  \; Innovation at Mayo Clinic &\; the Discovery Oasis\n\n \n\n \n\n Ste ven Lester\, MD\, Founder and Chief Medical Officer\, Mayo Clinic -ASU Med tech Accelerator\; Chief Medical Officer\, Discovery Oasis\n Aric Bopp\, Executive Director\, Discovery Oasis\n\n\n\n\n\n11:30 AM \;  \; &n bsp\;  \;  \;Innovation and Man's Best Friend\n\n \n\n \n\n Joh n Galgiani\, MD\, Director\, Valley Fever Center for Excellence\n Stephen Albert Johnston\, CEO and Chairman\, Calviri\n\n\n\n\n\n12:00PM \; &n bsp\;  \;  \;  \;Networking Lunch (Sponsored by Nguyen Tarbett LLC)\n\n1:00 \; PM \;  \;  \;  \; Moving Innovation F orward: The Impact of Governance on Funding (Sponsored by NACD)\n\n \n\n \n\n Michael Chambers\, Co-Founder Aldevron\n Jacque J. Sokolov\, MD\, NACD Pacific Southwest Chapter\, Arizona Advisory Board Co-Chair\n\n\n\n\n \n2:00 \; PM \;  \;  \; Accelerating Health Innovation in Arizona\n\n \n\n \n\n Elsa Abruzzo\, CEO\, Anuncia Medical\n Joan Koer ber-Walker\, President &\; CEO\, AZAdvances\n Jordan Lancaster\, CEO\, Avery Therapeutics\n Stan Miele\, President\, Aqualung Therapeutics\n R uss Yelton\, Trustee\, AZAdvances \;\n\n\n\n\n\n3:00 PM \;  \;  \;  \;Leadership Conversation\n\n \n\n \n\n Mathew Likens\, C EO\, GT Medical Technologies\n 2023 Arizona Bioscience Company of the Yea r\n\n\n\n\n\n4:00 PM \;  \;  \;  \; Closing Networking Rec eption\n\n5:00 PM \;  \;  \;  \;  \;Event Concludes\n\ n\n\nInnovation Showcase Presenters\nElsa Chi Abruzzo \; is CEO and Pr esident of Anuncia Medical a medical device executive\, entrepreneur\, and a founding member of Anuncia Medical\, Alcyone LifeSciences (now Alcyone Therapeutics)\, Arthromeda\, Inc. and Cygnus Regulatory (formerly ARAC) wi th a 33+ year successful product development\, operations\, regulatory\, q uality\, and clinical track record in med tech. Some of the disruptive med ical solutions Ms. Abruzzo has helped develop and bring to market include: transcatheter heart valves (TAVR)\, tissue heart valves\, implantable bio materials\, surgical adhesives\, embolic agents\, stents\, atrial fibrilla tion ablation devices\, LAA closure devices\, neuromodulation devices\, hu man tissues\, drug delivery systems and combination products\, orthopedic navigation systems\, microinvasive spinal implants\, tissue containment an d retrieval systems\, homeostasis devices\, and point of care lipid and gl ucose/A1c analyzers. She has authored or contributed to 4 granted US FDA B reakthrough Devices Designations. Ms. Abruzzo has a B.S. in engineering fr om the University of Miami (Coral Gables\, FL) and is regulatory affairs c ertified (RAC) and a Regulatory Affairs Professional Society (RAPS) Fellow (inducted in 2010). \;\n\nRichard Austin is a visionary biotech entre preneur and co-founder of Reglagene\, spearheading the development of grou ndbreaking therapies for the treatment of brain diseases. With an impressi ve career spanning over three decades in the pharmaceutical industry\, Ric hard brings a wealth of expertise and a deep passion for driving transform ative change in healthcare. \;Drawing on his strong background in labo ratory research and operations management\, Richard has played pivotal rol es across various critical aspects of the pharmaceutical industry. From dr ug development and testing to overseeing the business operations of pharma ceutical R&\;D\, he has consistently delivered outstanding results and successfully advanced new products throughout his career. \;\n\n\n\nMi chael Chambers co-founded Aldevron while studying Chemistry\, Microbiology \, and Biotechnology at North Dakota State University. It's a testament to teamwork and collaboration that Aldevron rapidly evolved from a small lab on the NDSU campus to a leading catalyst in the global genomic medicine s ector. Under Michael's stewardship as CEO until 2020\, the company became a collective powerhouse in manufacturing nucleic acids and recombinant enz ymes. These components are critical for revolutionary cell and gene therap ies\, gene-editing technologies\, and vaccines. \; \;\n\nIn 2021\, the culmination of years of collaborative work came to fruition when Dana her Corporation acquired Aldevron for $9.6 billion. Today\, Aldevron thriv es with 1\,000 associates between its Fargo\, ND headquarters and Madison\ , WI site.\n\nIn addition to Aldevron\, Michael serves on the board of Sar epta Therapeutics\, which recently celebrated the approval of its groundbr eaking gene therapy\, Elvidys\, for Duchenne Muscular Dystrophy. He's also a board member of MIT's prestigious Whitehead Institute\, further extendi ng his influence and commitment to groundbreaking research and innovation. His diversified interests include investments and leadership roles in tec hnology companies like Calviri\, Genovac\, and Agathos Bio\, as well as be ing a primary investor in the contemporary apparel company Oliver Cabell.& nbsp\;\n\nMichael's commitment to innovation and teamwork was recognized w hen he was named one of the 100 Most Intriguing Entrepreneurs by Goldman S achs in 2018 and one of the Top 25 Biotech CEOs of 2021 by Healthcare Tech nology Report. \;\n\nDespite a packed professional life\, Michael cher ishes his family time\, living with his wife and five daughters and dividi ng his time between homes in Fargo and Boston.\n\nJohn Galgiani\, MD\, is the Director of the Valley Fever Center for Excellence and \; Professo r\, Internal Medicine at the University of Arizona. \; Dr. Galgiani re ceived his MD from Northwestern Medical School and completed a fellowship in Infectious Diseases at Stanford. In 1978\, he joined the faculty of the University of Arizona where he has remained ever since\, currently as Pro fessor of Medicine. Dr. Galgiani has focused his career on the special pro blem of coccidioidomycosis\, also known as Valley fever. His work has incl uded studies of the impact of Valley fever on the general population and o n special groups such as organ transplant recipients and patients with AID S and is the lead author on the Infectious Diseases Society of America’s practice guidelines for coccidioidomycosis. In 1996\, Dr. Galgiani founde d the Valley Fever Center for Excellence. In collaboration with Banner Hea lth\, Dr. Galgiani developed and is now implementing a training program fo r primary care clinicians for prompt recognition and optimal management of patients with new Valley fever infections. The Center’s research has re cently developed a vaccine candidate to prevent Valley fever in dogs and p otentially in humans.\n\nMaryAnn Guerra has a career-long passion for brin ging technology to market\, accelerating innovation from the lab into comm ercial businesses and providing an incomparable client experience. As Foun der of Aesthetics Biomedical®\, she understands the importance of designi ng experiences that create results. As a client of her own company\, she v alues the opportunity to feel her very best at any age using leading-edge\ , FDA-cleared technology and treatment serums and recovery agents that tru ly make a difference. It is her privilege to advance these innovations thr ough a network of respected doctors and med spas to make an impact on the battle against aging for men and women. Guerra is tireless in her perpetua l pursuit of perfection and her never-ending quest to turn innovation into results. Guerra has spent much of her career operating successful and pro gressive health\, science\, technology and start-up businesses. Guerra ser ved as President of TGen Accelerators\, LLC and Chief Operating Officer at TGen. Guerra has also had an impressive career at the National Institutes of Health\, having held senior level positions\, including: Executive Off icer\, National Heart Lung and Blood Institute and Deputy Director of Mana gement &\; Executive Officer at the National Cancer Institute.\n\nSteph en Albert Johnston is the Chief Executive Officer &\; Chairman of the B oard of Calviri and is also the \;inventor of the Calviri’s central technologies. Calviri’s mission is to provide affordable products worldw ide that will end suffering from cancer by combining a unique\, highly imm unogenic source of neoantigens with its peptide array platform. The team i s developing new diagnostic and therapeutic products\, and then preventati ve vaccines that will stop cancer from starting. In addition to Calviri\, he has been a founder of Eliance\, Inc. (Macrogenics)\, Synbody Biotechnol ogy and HealthTell\, Inc. He is Director of the Arizona State University B iodesign Institute’s Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed pa pers and holds 45 patents. Prior to his appointment at ASU he was Professo r and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. John ston received his B.S. and Ph.D. degrees from the University of Wisconsin. \n\n\n\nJoan Koerber-Walker serves as President and CEO of the \;Arizo na Bioindustry Association\, Inc. (AZBio). She works on behalf of the Ariz ona Bioscience and Medical Technology Industry to support the growth of th e industry\, its members and our community on the local and national level . Joan is also a life science investor and has served on the boards of num erous for-profit and non-profit organizations. AZBio \; Member Organiz ations \;in the fields of business\, research and education\, health c are delivery\, economic development\, government\, and other professions i nvolved in the biosciences are the key drivers of the growth of Arizona’ s life science sector.  \;As the unified voice of our industry in Ariz ona\, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.\nJordan Lancaster is the co-founder and Chief Execu tive Officer of Avery Therapeutics Inc. \; Dr. Lancaster has dedicated his career to developing biologic therapeutics to improve the lives of pa tients afflicted with heart disease. \;He began his career as an Assis tant Professor at the University of Arizona College of Medicine and member of the Sarver Heart Center where he led multi-disciplinary research teams . \; His work over the past decade has focused on the intersection of cell biology\, biomaterials\, and cardiovascular physiology. His work has led to the development of bio-fabricated tissue platforms which create tun able and distinctive biological niches. \;He currently serves on the A lliance of Regenerative Medicine’s Biomaterials and Tissue Engineering c ommittee and was named a Senior Member of the National Academy of Inventor s. Dr. Lancaster earned his PhD in Physiology and a BS in Molecular and Ce llular Biology both from the University of Arizona. \;\n\n\nMatthew Li kens\, CEO of GT Medical Technologies\, \; is an accomplished leader i n the medical device industry. He joined GT Medical Technologies because h e was inspired by the company’s powerful purpose of “Improving the liv es of patients with brain \;tumors." \; Prior to coming to GT Medi cal Technologies\, he served as the president and chief executive officer of Ulthera\, Inc. There\, he led the startup from pre-commercialization to more than $100M in revenue and a $600M acquisition by Merz Pharma \;G mbH. Matt's professional career began with Johnson &\; Johnson. However \, he spent the bulk of his career at Baxter Healthcare Corporation\, wher e he progressed through a variety of domestic and international sales\, ma rketing\, and general management roles that ultimately culminated in the p osition of president of Baxter Biotech North America\, and then the presid ent of its US Renal Care division. After departing Merz in mid-2016\, Like ns joined the board of Luma Therapeutics\, a startup with a novel approach for the treatment of psoriasis\, and CHF Solutions\, a NASDAQ-listed comp any focused on supporting patients suffering from congestive heart failure due to fluid \;overload.\n\nStan Miele\, President of Aqualung Therap eutics is a recognized global executive with success in sales\, marketing and P&\;L leadership in the pharmaceutical/medical device and biotech i ndustries. Mr. Miele was formally the Chief Commercial Officer at bioLytic al Laboratories and Sucampo Pharmaceuticals Inc. \; He was also Presid ent of Sucampo Pharma Americas for 6 years. \; \; He was instrumen tal on some key licensing agreements for Sucampo\, inclusive of the agreem ent with Abbott Japan\, and also Takeda Pharmaceuticals (now Shire). \ ; He is actively part of the team ensuring proper execution of clinical de velopment\, manufacturing\, licensing\, capital funding\, alliances\, and ensuring Aqualung meets all critical milestones. \; He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.\n\n\n\nRichard J. Morello&nb sp\;joined CND \;Life Sciences \;as CEO in early 2020 and brings 2 5 years of experience with health and life sciences companies\, serving in senior executive roles globally for medical device\, digital health\, and diagnostics firms. Prior to joining CND \;as CEO\, Rick was the Globa l President of Life Sciences at Aptus Health\, a former subsidiary of Merc k\, Inc. (acquired by WebMD) and CEO of Plasma Surgical\, an innovative me dical device company with technology used in open and laparoscopic procedu res around the world. Rick began his career in strategy consulting\, risin g to Partner at Mercer Management Consulting where he helped build the Hea lth &\; Life Sciences Practice and managed large biopharma and diagnost ics clients. A Kellogg MBA and graduate of the University of Virginia\, Ri ck also founded and helped grow three nonprofit organizations that have ra ised nearly $100 million in the last decade to fulfill health and social i mpact missions including Family Reach Foundation\, \;which was include d in the Obama White House’s Cancer Moonshot in 2016.\n\n\n\nJacque J. S okolov\, M.D. is chairman and chief executive officer of the SSB\, a diver sified U.S. based\, healthcare management\, development\, and investment c ompany. Its four strategic businesses include SSB Solutions\, SSB Investme nt Funds\, SSB Financial Services and SSB Governmental Services. As CEO\, Dr. Sokolov leads SSB’s four strategic business units to optimize health care solutions\, investment strategies\, financial structures\, and govern mental contracting. SSB was founded on the premise of developing high qual ity\, value-based solutions in rapidly evolving markets. The company opera tes across the United States and has worked with more than 100 healthcare companies in virtually every healthcare sector. Dr. Sokolov and the SSB te am have been vital to large healthcare corporations to reimagine their bus iness models and improve and increase performance at critical inflection p oints in their history. Some of his projects include redesigning health pl ans such as the Humana Inc. turnaround/adoption of consumer facing interne t-based technology in 2000\, the transition of Hospira from an I.V. soluti on company to the largest independent biosimilar manufacturer in the world that Pfizer acquired for $17 billion in 2015. In addition\, Dr. Sokolov w as active in the development of physician practice management companies su ch as the Summit Medical Group evolving to Summit Health/CityMD resulting in a $9B merger with VillageMD/Walgreens/Cigna in 2022. \;\n\n\n\nKris ten Swingle serves as President and Chief Operating Officer of the Critica l Path Institute (C-Path). \; Prior to joining C-Path in 2019\, Kriste n served as the VP of Stem Cell Operations at Cord Blood Registry where sh e was responsible for overseeing all operations at CBR’s laboratory in T ucson\, Arizona\, since 2007. \; \;Kristen has over two decades’ worth of experience in the medical and molecular sciences industry with a strong background in product development and manufacturing\, quality and regulatory affairs management\, project and fiscal management\, and team l eadership. \; As President &\; COO of C-Path\, she is responsible f or the daily operations of the organization and development and implementa tion of C-Path’s global strategy and goals. \; \;Kristen also se rves as a member of the AZBio Board of Directors and was elected Chairwoma n in January 2018. CATEGORIES:AZ - Central,AZ - North,AZ- South LOCATION:ASU Health Futures Center\, 6161 E Mayo Blvd\, Phoenix\, AZ\, 8505 4\, United States X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=6161 E Mayo Blvd\, Phoenix\ , AZ\, 85054\, United States;X-APPLE-RADIUS=100;X-TITLE=ASU Health Futures Center:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20220928T100000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR